Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 27:6:253-9.
doi: 10.2147/CMAR.S40601. eCollection 2014.

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

Maria Y Ho  1 , John R Mackey  1
Affiliations
Review

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

Maria Y Ho et al. Cancer Manag Res. .

Abstract

The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion reactions, febrile neutropenia, fatigue, fluid retention, pneumonitis, cutaneous and nail toxicity, epiphora and lacrimal duct stenosis, gastrointestinal complications, and neuropathies. In this review, we explore these complications and how they can be effectively managed to improve patient quality of life during and following docetaxel therapy.

Keywords: adverse events; chemotherapy; toxicity.

PubMed Disclaimer

References

    1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–1792. - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al., editors. The Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975–2008. National Cancer Institute; Bethesda, MD: 2010. [Accessed May 10, 2014]. Available from: http://seer.cancer.gov/csr/1975_2008/index.html.
    1. van der Hage JA, Mieog JS, van de Velde CJ, Putter H, Bartelink H, van de Vijver MJ. Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res. 2011;13(3):R68. - PMC - PubMed
    1. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. - PMC - PubMed
    1. Peto R, Davies C, Godwin J, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444. - PMC - PubMed

LinkOut - more resources